Abstract
Background Improved diagnostic capabilities and accessibility are essential for controlling the outbreak of Human Monkeypox.
Methods We describe a saliva-based polymerase chain reaction (PCR) assay for Human Monkeypox, in vitro test performance, and clinical implementation of that assay at three testing sites in Los Angeles. Finally, using pre-specified search terms, we conducted a systematic rapid review of PubMed and Web of Science online databases of studies reporting the performance of oral pharyngeal or saliva-based tests for Human Monkeypox.
Results Laboratory evaluation of the assay showed in silico inclusivity of 100% for 97 strains of Human Monkeypox, with an analytic sensitivity of 250 copies/mL, and 100% agreement compared to known positive and negative specimens. Clinical testing identified 22 cases of Human Monkeypox among 132 individuals (16.7%). Of those 22 cases, 16 (72.7%) reported symptoms, 4 (18.2%) without a rash at the time of testing. Our systematic rapid review identified 6 studies; 23 patients had tests performed on oropharyngeal specimens 100% agreed with the PCR test result of a lesion swab.
Conclusion Saliva-based PCR tests are potential tools for outbreak control, and further evaluation of the performance of such tests is warranted.
Competing Interest Statement
Lao-Tzu Allan-Blitz served as a consultant for Curative Inc., Jeffrey D. Klausner served as an independent medical director of Curative Inc. Hong Li is the laboratory director for Flow Health.
Funding Statement
This research was supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra institutional review committee exempted the analysis of de-identified data from institutional review (Pro00065270).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: Lao-Tzu Allan-Blitz served as a consultant for Curative Inc., Jeffrey D. Klausner served as an independent medical director of Curative Inc. Hong Li is the laboratory director for Flow Health.
Data Availability
Data are available upon request
